Loading viewer...
investor_presentation
Format: PDF investor_presentation
DSM-Firmenich presents FY 2023 results following successful merger integration, highlighting merger synergies gaining traction despite challenging vitamin market conditions. The company outlines strategic actions including vitamin transformation programs, planned Animal Nutrition & Health separation, and mid-term targets aimed at portfolio strengthening and improved earnings potential.
investor_presentation
33 Pages
ePlus
investor_presentation
Aramark